Safety and Efficacy Study of Altabax Ointment in the Treatment of Secondarily Infected Atopic Dermatitis

Inclusion Criteria: * Female subjects of childbearing potential must have a negative urine pregnancy test at Baseline and practice a reliable method of contraception. * Secondary infection of atopic dermatitis with S.aureus or S.pyogenes as the probable causative agent. * An infected area less than or equal to 100 centimeters squared for subjects 18 years of age or older, or, 2% body surface area for subjects under 18 years of age. * Skin Infection Rating Scale score greater than or equal to 8. * Able to understand and comply with the requirements of the study and sign Informed Consent/Health Insurance Portability and Accountability Authorization Forms. Subjects under the legal age of consent must also have the written informed consent of parent or legal guardian. Exclusion Criteria: * Female subjects who are pregnant, trying to get pregnant, breast feeding or who are of childbearing potential and not practicing reliable birth control. * Allergic to any component of the test medication. * Clinical diagnosis of impetigo, folliculitis or minor soft tissue infection. * Use of topical antibacterial medication to the study treatment area within 1 day of Visit 1. * Signs of systemic infection or evidence of abcess or cellulitis at the site to be treated. * Medical condition that,in the opinion of the investigator, contraindicates the subject's participation in the clinical study. * Recent alcohol or drug abuse is evident. * History of poor cooperation, non-compliance with medical treatment or unreliability. * Participation in an investigational drug study within 30 days of Baseline Visit.